Kenneth C. Cundy
2022 - Anebulo Pharmaceuticals
In 2022, Kenneth C. Cundy earned a total compensation of $490.4K as Chief Scientific Officer at Anebulo Pharmaceuticals.
Compensation breakdown
| Option Awards | $450,421 |
|---|---|
| Salary | $39,936 |
| Total | $490,357 |
Cundy received $450.4K in option awards, accounting for 92% of the total pay in 2022.
Cundy also received $39.9K in salary.
Rankings
In 2022, Kenneth C. Cundy's compensation ranked 4,368th out of 5,753 executives tracked by ExecPay. In other words, Cundy earned more than 24.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,368 out of 5,753 | 24th |
Division Manufacturing | 2,455 out of 3,133 | 22nd |
Major group Chemicals And Allied Products | 1,188 out of 1,419 | 16th |
Industry group Drugs | 1,115 out of 1,320 | 16th |
Industry Pharmaceutical Preparations | 813 out of 966 | 16th |
Source: SEC filing on October 17, 2022.
Cundy's colleagues
We found three more compensation records of executives who worked with Kenneth C. Cundy at Anebulo Pharmaceuticals in 2022.
News
Anebulo Pharmaceuticals CEO Simon Allen's 2023 pay falls 63% to $778K
October 30, 2023
Anebulo Pharmaceuticals CEO Simon Allen receives $2.1M in 2022
October 17, 2022
CohBar CEO Joseph Sarret receives $3.2M in 2021
April 22, 2022
CohBar CEO Steven Engle receives $2.4M in 2019
April 29, 2020
CohBar CEO Philippe Calais receives $1.6M in 2018
April 24, 2019